Enhancing chimeric antigen receptor T‐cell immunotherapy against cancer using a nanoemulsion‐based vaccine targeting cross‐presenting dendritic cells

Enhancing chimeric antigen receptor T‐cell immunotherapy against cancer using a nanoemulsion‐based vaccine targeting cross‐presenting dendritic cells

Abstract Objectives Adoptive transfer of chimeric antigen receptor (CAR)‐modified T cells is a form of cancer immunotherapy that has achieved remarkable efficacy in patients with some haematological cancers. However, challenges remain in CAR T‐cell treatment of solid tumours because of tumour‐mediat...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Jack D Chan, Bianca vonScheidt, Bijun Zeng, Amanda J Oliver, Ashleigh S Davey, Aesha I Ali, Ranjeny Thomas, Joseph A Trapani, Phillip K Darcy, Michael H Kershaw, Riccardo Dolcetti, Clare Y Slaney
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Wiley 2020-01-01
Sarja:Clinical & Translational Immunology
Aiheet:
CAR T cells
Clec9A
cross‐presentation
dendritic cells
nanoemulsion
vaccine
Linkit:https://doi.org/10.1002/cti2.1157

Internet

https://doi.org/10.1002/cti2.1157

Samankaltaisia teoksia